Topp 6 verdipapirfond med FP1 / Salarius Pharmaceuticals, Inc. (DB).

Salarius Pharmaceuticals, Inc.
DE ˙ DB
€ 12,91 ↑0,01 (0,08%)
2019-07-25
AKSJEKURSEN
Topp 6 verdipapirfond med DE:FP1 / Salarius Pharmaceuticals, Inc.

Denne siden viser alle aksjefond som har rapportert posisjoner i DE:FP1 / Salarius Pharmaceuticals, Inc.. Grønne rader indikerer nye posisjoner. Klikk på lenkeikonet for å se hele transaksjonshistorikken.

Oppgrader for å låse opp premiumdata og eksportere til Excel .

Fildato Kilde Investor Type Gjennomsnittlig pris
(estimert)		 Aksjer Δ Aksjer
(%)		 Rapportert verdi ($1000) Verdi (%) Portallokering (%)
2025-04-25 NP FNCMX - Fidelity Nasdaq Composite Index Fund This fund is a listed as child fund of Fmr Llc and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value 0 −100,00 0
2025-08-27 NP VEXMX - Vanguard Extended Market Index Fund Investor Shares This fund is a listed as child fund of Vanguard Group Inc and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value 1 820 0,00 2 0,00
2025-07-24 NP FSMAX - Fidelity Extended Market Index Fund This fund is a listed as child fund of Fmr Llc and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value 9 353 64,78 7 16,67
2025-03-28 NP USMIX - Extended Market Index Fund 0 −100,00 0
2025-07-24 NP FCFMX - Fidelity Series Total Market Index Fund This fund is a listed as child fund of Fmr Llc and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value 7 028 323,63 5 400,00
2025-07-24 NP FSKAX - Fidelity Total Market Index Fund This fund is a listed as child fund of Fmr Llc and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value 321 0,00 0
Other Listings
US:SLRX USD 5,25
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista

© 2015-2025 Fintel Ventures LLC. All rights reserved. Fintel® is a registered trademark.

This website is provided “as is” without any representations or warranties, express or implied. Fintel makes no representations or warranties in relation to this website or the information and materials provided on this website. Nothing on this website constitutes, or is meant to constitute, advice of any kind. If you require advice in relation to any financial matter you should consult an appropriate professional.

About Fintel
Top Investors
Features
Explore
Help Center